First-in-human, phase 1a dose finding of LVGN6051 CD137/4-1BB agonistic antibody with or without pembrolizumab in patients with advanced solid tumors

被引：0
作者：
Daud, Adil
Albany, Costantine
Velcheti, Vamsidhar
Hauke, Ralph J.
Ahnert, Jordi Rodon
Karp, Daniel D.
Tsimberidou, Apostolia Maria
Cohen, Julia Wanda
Schmidt, Emmett V.
Wang, Jieyi
Chan, C. Hubert
Fu, Siqing
机构：
[1] Univ Calif San Francisco, San Francisco, CA USA
[2] Horizon Oncol & Res Ctr, Lafayette, IN USA
[3] NYU, New York, NY USA
[4] Laura & Isaac Perlmutter Canc Ctr, New York, NY USA
[5] Nebraska Canc Specialists, Omaha, NE USA
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[7] Merck Co Inc, Rahway, NJ USA
[8] Lyvgen Biopharma, Shanghai, Peoples R China
[9] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2525
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase 1 trial safety and efficacy of ragistomig, a bispecific antibody targeting PD-L1 and 4-1BB, in advanced solid tumors
    Falchook, Gerald Steven
    LoRusso, Patricia
    Goldman, Jonathan W.
    El-Khoueiry, Anthony B.
    Tolcher, Anthony W.
    Xing, Yan
    Henry, Jason Timothy
    Keam, Bhumsuk
    Kim, Dong-Wan
    Kim, Tae-Yong
    Kim, Hye Ryun
    Hong, Min Hee
    Kim, Min Hwan
    Lee, Dae Ho
    Lee, SangMi
    Jeon, JuYeun
    Hayslip, John W.
    Xu, Cong
    Garon, Edward B.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [32] A phase 1, dose escalation/dose-expansion study of QLF31907, a bispecific antibody (BsAb) targeting PD-L1 and 4-1BB, in patients with advanced solid tumors and lymphoma
    Lin, Tongyu
    Liu, Bin
    Pu, Xingxiang
    Wu, Lin
    Du, Xiaobo
    Mo, Ning
    Song, Zhengbo
    Zhou, Liwei
    Duan, Xianlin
    Zhu, Yanan
    Kang, Xiaoyan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] First-in-human phase I of anti-VISTA monoclonal antibody W0180 with and without anti-PD-1 pembrolizumab in patients with locally advanced or metastatic solid tumors
    Gomez-Roca, Carlos
    Champiat, Stephane
    Cassier, Philippe
    Jegou, David
    Primard, Marie
    Petain, Aurelie
    Gueguen-Dorbes, Genevieve
    Fabre, Claire
    Melero, Ignacio
    Marabelle, Aurelien
    CANCER RESEARCH, 2024, 84 (07)
  • [34] First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors
    Bauer, Todd
    Cho, Byong Chul
    Heist, Rebecca
    Bazhenova, Lyudmila
    Werner, Theresa
    Goel, Sanjay
    Kim, Dong-Wan
    Adkins, Douglas
    Carvajal, Richard D.
    Alva, Ajjai
    Eaton, Keith
    Wang, Judy
    Liu, Yong
    Yan, Xiaohong
    Christensen, Jamie
    Neuteboom, Saskia
    Chao, Richard
    Pant, Shubham
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (05) : 990 - 1000
  • [35] Phase 1 first-in-human study of dalutrafusp alfa, an anti-CD73-TGF-β-trap bifunctional antibody, in patients with advanced solid tumors
    Tolcher, Anthony W.
    Gordon, Michael
    Mahoney, Kathleen M.
    Seto, Anna
    Zavodovskaya, Marianna
    Hsueh, Chia-Hsiang
    Zhai, Shuyan
    Tarnowski, Thomas
    Jurgensmeier, Juliane M.
    Stinson, Susanna
    Othman, Ahmed A.
    Chen, Tianling
    Strauss, James
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (02)
  • [36] First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors
    Todd Bauer
    Byong Chul Cho
    Rebecca Heist
    Lyudmila Bazhenova
    Theresa Werner
    Sanjay Goel
    Dong-Wan Kim
    Douglas Adkins
    Richard D. Carvajal
    Ajjai Alva
    Keith Eaton
    Judy Wang
    Yong Liu
    Xiaohong Yan
    Jamie Christensen
    Saskia Neuteboom
    Richard Chao
    Shubham Pant
    Investigational New Drugs, 2022, 40 : 990 - 1000
  • [37] A first-in-human phase I study of FS120, an OX40/CD137 tetravalent bispecific antibody, in patients with advanced malignancies
    Papadopoulos, K.
    Yap, T. A.
    Piha-Paul, S. A.
    Lorusso, P.
    Hu-Lieskovan, S.
    Shepherd, C. J.
    Marshall, S.
    Holz, J-B.
    Poon, E.
    Grabowska, U. B.
    Kayitalire, L.
    ANNALS OF ONCOLOGY, 2021, 32 : S864 - S865
  • [38] A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors
    Victor Moreno
    Ruth Perets
    Tamar Peretz-Yablonski
    Nele Fourneau
    Suzette Girgis
    Yue Guo
    Peter Hellemans
    Raluca Verona
    Natalia Pendás
    Qi Xia
    Ravit Geva
    Emiliano Calvo
    Investigational New Drugs, 2023, 41 : 93 - 104
  • [39] Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity
    Kotanides, Helen
    Sattler, Rose Marie
    Lebron, Maria B.
    Carpenito, Carmine
    Shen, Juqun
    Li, Jingxing
    Surguladze, David
    Haidar, Jaafar N.
    Burns, Colleen
    Shen, Leyi
    Inigo, Ivan
    Pennello, Anthony L.
    Forest, Amelie
    Chen, Xinlei
    Chin, Darin
    Sonyi, Andreas
    Topper, Michael
    Boucher, Lauren
    Sharma, Prachi
    Zhang, Yiwei
    Burtrum, Douglas
    Novosiadly, Ruslan D.
    Ludwig, Dale L.
    Plowman, Gregory D.
    Kalos, Michael
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (04) : 988 - 998
  • [40] Phase 1 dose escalation study of DSP107, a first-in-class CD47 and 4-1BB targeting multifunctional immune-recruitment protein, in patients with advanced solid tumors
    Luke, Jason J.
    Saeed, Anwaar
    Bashir, Babar
    Shwartz, Yaffa
    Tabakman, Rinat
    Foley-Comer, Adam
    Jimeno, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345